Since January 2020, Elsevier has established a COVID-19 resource center on its public news and information website, Elsevier Connect, providing free English and Mandarin information about the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights, as long as the resource center remains active. The article also discusses the potential use of baricitinib as a treatment for 2019-nCoV acute respiratory disease. Using BenevolentAI's knowledge graph, researchers identified baricitinib, which is predicted to reduce the virus's ability to infect lung cells by inhibiting AAK1, a regulator of endocytosis. While other AAK1 inhibitors like sunitinib and erlotinib have been shown to inhibit viral infection, they come with serious side effects. Baricitinib, a janus kinase inhibitor, is suggested for further trials due to its therapeutic plasma concentration and potential to reduce both viral entry and inflammation in patients with 2019-nCoV acute respiratory disease.Since January 2020, Elsevier has established a COVID-19 resource center on its public news and information website, Elsevier Connect, providing free English and Mandarin information about the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights, as long as the resource center remains active. The article also discusses the potential use of baricitinib as a treatment for 2019-nCoV acute respiratory disease. Using BenevolentAI's knowledge graph, researchers identified baricitinib, which is predicted to reduce the virus's ability to infect lung cells by inhibiting AAK1, a regulator of endocytosis. While other AAK1 inhibitors like sunitinib and erlotinib have been shown to inhibit viral infection, they come with serious side effects. Baricitinib, a janus kinase inhibitor, is suggested for further trials due to its therapeutic plasma concentration and potential to reduce both viral entry and inflammation in patients with 2019-nCoV acute respiratory disease.